Asset Management One Co. Ltd. Boosts Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Asset Management One Co. Ltd. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,172 shares of the medical equipment provider's stock after purchasing an additional 6,144 shares during the period. Asset Management One Co. Ltd. owned approximately 0.07% of Hologic worth $9,338,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Dark Forest Capital Management LP lifted its stake in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after acquiring an additional 223 shares during the period. Baker Avenue Asset Management LP boosted its holdings in shares of Hologic by 0.5% during the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after acquiring an additional 225 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the period. Finally, Integrated Advisors Network LLC raised its holdings in shares of Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Raymond James Financial restated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Evercore ISI dropped their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Stephens cut their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of "Hold" and an average price target of $77.42.

Hologic Price Performance

NASDAQ HOLX traded down $0.10 during trading hours on Friday, reaching $65.01. The company's stock had a trading volume of 3,320,131 shares, compared to its average volume of 2,369,901. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $14.49 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 2.38 and a beta of 0.55. The firm's 50-day moving average price is $60.00 and its 200-day moving average price is $63.98.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter last year, the business posted $1.03 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.